Exposure to the cannabinoid agonist WIN 55, 212–2 in adolescent rats causes sleep alterations that persist until adulthood

Lorena Macías-Triana, Karen Romero-Cordero, Agnes Tatum-Kuri, Alba Vera-Barrón, Diana Millán-Aldaco, Gloria Arankowsky-Sandoval, Daniele Piomelli, Eric Murillo-Rodríguez

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Cannabis and, to a lesser extent, synthetic cannabinoids are used during adolescence, a period in which multiple brain areas are still undergoing development. Among such areas is the hypothalamus, which is implicated in the control of sleep-wake cycle. In the present report, we show that exposing adolescent rats to the cannabinoid receptor agonist WIN 55, 212–2 (0.1, 0.3 or 1.0 mg/kg, i.p) for 14 days during adolescence (i.e., from post-natal day 30–44) resulted in significant sleep disturbances when the animals became adult (post-natal day 80). These included decreased wakefulness and enhanced rapid eye movement sleep. Furthermore, we found that labeling for NeuN, a marker of postmitotic neurons, was significantly increased the dorsomedial hypothalamic nucleus of rats treated with WIN 55, 212–2. The results suggest that excessive cannabinoid receptor activation during adolescence can persistently influence sleep patterns and neuronal activity later in life.

Original languageEnglish
Article number172911
JournalEuropean Journal of Pharmacology
Volume874
DOIs
StatePublished - 5 May 2020

Keywords

  • Adolescence
  • Cannabinoids
  • Rapid eye movement sleep
  • Sleep
  • WIN 55,212–2

Fingerprint

Dive into the research topics of 'Exposure to the cannabinoid agonist WIN 55, 212–2 in adolescent rats causes sleep alterations that persist until adulthood'. Together they form a unique fingerprint.

Cite this